
1. cancer gene ther. 2011 apr;18(4):240-9. doi: 10.1038/cgt.2010.73. epub 2010 nov
19.

novel adenovirus-based helper system support production recombinant
parvovirus.

el-andaloussi n(1), endele m, leuchs b, bonifati s, kleinschmidt j, rommelaere j,
marchini a.

author information: 
(1)infection cancer program, german cancer research center (dkfz),
heidelberg, germany.

preclinical studies using various cell culture animal systems highlight the
potential recombinant rodent parvoviruses (recpvs) cancer therapy.
production viruses is, however, efficient hampers the
clinical applications agents. study, show adenovirus
genes e2a, e4(orf6) va rna increase production recpvs than
10-fold reduce time production 3 2 days hek293t cells. 
helper effects genes observed different recpvs, regardless
of nature size inserted transgene. furthermore, generated a
recombinant adenovirus 5 carrying parvovirus vp transcription unit. this
helper, named ad-vp, allows recpvs efficiently produced protocol 
based cell infection, making possible use cell lines, nb324k, 
which good producers parvoviruses hardly transfectable. hence, 
could improve viral titers reduce time costs production. 
ad-vp helper-based protocol could scaled bioreactor format the
generation large amounts recpvs needed future clinical
applications.

doi: 10.1038/cgt.2010.73 
pmid: 21102423  [indexed medline]

